接受连续肾脏替代治疗的重症患者中高剂量黏菌素的药代动力学
本研究在3个ICU纳入20例碳青霉烯耐药鲍曼不动杆菌呼吸机相关性肺炎并接受CRRT的重症患者,给予9 MIU负荷剂量后6.75 MUI q12静脉CMS,第7剂后24小时采血行PK/PD分析。中位峰浓度16.6 mcg/mL、谷浓度3.9 mcg/mL,AUC0-24为193.9 mcg h/mL,Css,avg为8.07 mcg/mL。按fAUC0-24/MIC≥12的靶目标,MIC≤2 mcg/mL时达标概率100%,MIC=4 mcg/mL时85%,但Css,avg超过3-4 mcg/mL的毒性上限。作者结论认为该推荐剂量使黏菌素血浆水平超过细菌MIC90,但超过安全性Css,avg上限。
要点
- 20例CRRT重症患者用CMS 9 MIU负荷后6.75 MUI q12,第7剂后中位峰浓度16.6 mcg/mL、谷浓度3.9 mcg/mL。
- 中位AUC0-24为193.9 mcg h/mL,Css,avg为8.07 mcg/mL,超过3-4 mcg/mL的毒性上限。
- fAUC0-24/MIC≥12达标概率:MIC≤2 mcg/mL为100%,MIC=4 mcg/mL为85%。
- ICU期间15例死亡,6例肾功能恢复。
- 作者结论:推荐CMS剂量使黏菌素血浆水平超过细菌MIC90,但超过安全性Css,avg上限。
适用人群与场景
- 三家ICU连续纳入的接受CRRT、因碳青霉烯耐药(CR)细菌感染使用黏菌素至少48小时的重症患者。
- 20例均为CR-鲍曼不动杆菌呼吸机相关性肺炎,中位SAPS II 41 [34.5-59.3]、SOFA评分9 [6.7-11]。
诊断标准与关键阈值
- 药效学靶目标为fAUC0-24/MIC≥12。
- 毒性上限为Css,avg 3-4 mcg/mL。
处置流程与药物剂量
- CMS静脉给药:9 MIU负荷剂量,随后6.75 MUI q12,至少48小时。
- 第7剂后24小时内进行系列血样采集行PK/PD分析。
研究设计与关键结果
- 研究类型:在3个ICU开展的前瞻性药代动力学/药效学研究,纳入20例接受CRRT的重症CR-鲍曼不动杆菌呼吸机相关性肺炎患者。
- 干预:CMS 9 MIU负荷后6.75 MUI q12静脉给药,第7剂后24小时采血。
- 主要PK结果:中位峰浓度16.6 mcg/mL [14.8-20.6],谷浓度3.9 mcg/mL [3.3-4.4],AUC0-24 193.9 mcg h/mL [170.6-208.6],Css,avg 8.07 mcg/mL [7.1-8.7]。
- 靶目标达标概率:fAUC0-24/MIC≥12时,MIC≤2 mcg/mL为100%,MIC=4 mcg/mL为85%,但Css,avg超过3-4 mcg/mL毒性上限。
- 临床结局:ICU期间15例死亡,6例肾功能恢复。
证据类型、等级与局限
- 证据类型:在3个ICU开展的前瞻性药代动力学/药效学研究,样本量20例。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在接受CRRT的重症CR感染患者中,推荐的CMS剂量使黏菌素血浆水平超过细菌MIC90,但超过安全性Css,avg上限。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Colistin, administered as intravenous colistimethate (CMS), is still used in the critical care setting and current guidelines recommend high dosage CMS in patients undergoing continuous renal replacement therapy (CRRT). Due to the paucity of real-life data, we aimed to describe colistin pharmacokinetic/pharmacodynamic (PK/PD) profile in a cohort of critically ill patients with infections due to carbapenem-resistant (CR) bacteria undergoing CRRT.
RESULTS: All consecutive patients admitted to three Intensive Care Units (ICUs) of a large metropolitan University Hospital, treated with colistin for at least 48 h at the dosage of 6.75 MUI q12, after 9 MIU loading dose, and undergoing CRRT were included. After the seventh dose, patients underwent blood serial sampling during a time frame of 24 h. We included 20 patients, who had CR-Acinetobacter baumannii ventilator-associated pneumonia and were characterized by a median SAPS II and SOFA score of 41 [34.5-59.3] and 9 [6.7-11], respectively. Fifteen patients died during ICU stay and six recovered renal function. Median peak and trough colistin concentrations were 16.6 mcg/mL [14.8-20.6] and 3.9 mcg/mL [3.3-4.4], respectively. Median area under the time-concentration curve (AUC0 - 24) and average steady-state concentration (Css, avg) were 193.9 mcg h/mL [170.6-208.6] and 8.07 mcg/mL [7.1-8.7]. Probability of target attainment of colistin pharmacodynamics according to the fAUC0 - 24/MIC target ≥ 12 was 100% for MIC ≤ 2 mcg/mL and 85% for MIC = 4 mcg/ML, although exceeding the toxicity limit of Css, avg 3-4 mcg/mL.
CONCLUSIONS: In critically ill patients with CR infections undergoing CRRT, recommended CMS dosage resulted in colistin plasmatic levels above bacterial MIC90, but exceeding the safety Css, avg. limit.
TRIAL REGISTRATION: This trial was registered in ClinicalTrials.gov on 23/07/2021 with the ID NCT04995133 (https//clinicaltrials.gov/study/NCT04995133).
参考来源
- De Pascale G, Lisi L, Cutuli SL, et al. High-dose colistin pharmacokinetics in critically ill patients receiving continuous renal replacement therapy. Ann Intensive Care. 2024. PMID: 39340688. doi:10.1186/s13613-024-01384-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。